 Home > Active Ingredient News > Drugs Articles > From the Spring Festival Gala in the pharmaceutical world, overseas "attack", to the birth of the "new crown miracle medicine"... Top ten famous scenes in the pharmaceutical industry in 2022

From the Spring Festival Gala in the pharmaceutical world, overseas "attack", to the birth of the "new crown miracle medicine"... Top ten famous scenes in the pharmaceutical industry in 2022

 Last Update: 2023-02-03
 Source: Internet
 Author: User

Tags

medicine induce vomiting

anticonvulsants list

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Open 2022, many "famous scenes" have swept in, and major events in the medical industry have been "stubble after stubble"
.

"The first domestic PD-1 to break through the FDA" can be called the "Spring Festival Gala in the pharmaceutical world"; A series of US policies have constrained it to become the "biggest assassin" of domestic pharmaceutical companies' overseas development; China Resources' large-scale acquisition of Kunming Medicine has brought about the birth of a "strong alliance" in the field of traditional Chinese medicine; Hengrui's series of executive changes have torn open the mouth of "how should traditional pharmaceutical companies build their own talent system"; The Kewang Selling Factory seems to have opened the "selling tide" Pandora's box; There is also "one buy and one sell", in the torrent of time, can "justify" for their own "right" of Genting Xinyao.
.
.
And the most annual joke is that ibuprofen was dubbed the "new crown miracle medicine" at the end of the year, which may have surprised the father of ibuprofen
.

This year, "not all biotechs have to be Big pharma" has almost become an industry consensus; This year, people from all walks of life in the industry have become clearer about their positioning, most of them strive to maximize their strength, and their behaviors and motivations can be followed
.

The hustle and bustle and doubts faded, and in terms of individual events, there may be joy and sorrow
.
But whether it is failure or success, the breakthroughs of China's innovative pharmaceutical companies from all directions have contributed to the vigorous development of China's biopharmaceutical industry
.

It was a year
destined to go down in history.
At the end of the year, E drug managers sorted out the "2022 Top Ten Pharmaceutical Industry Events" with certain industry value and benchmarking significance to review the whole year
of 2022.
The following are sorted by time:

01 "Cinda PD-1 Breakthrough FDA" Apocalypse of Going to Sea

On the evening of February 10, as the first domestic PD-1 to break through the FDA, the "Innovent PD-1 Overseas Journey" pressed the pause button
with the FDA Cancer Drug Advisory Committee "14:1".

This game between the two sides for nearly 5 hours, the excitement can be called a "Spring Festival Gala of the pharmaceutical world", hundreds of thousands of pharmaceutical people guarding the "live broadcast" of different platforms, this is not only a battle of a certain enterprise, but a "companion exam" related to the fate of the entire industry, everyone is waiting for the dawn to break and shine on the eastern continent
.

It is certain that regardless of the success of the pass, it has become a significant stroke in the history of Chinese medicine's overseas expansion, and has an important wind vane role and milestone significance
.
Judging from the results, on the one hand, the incident suggests the importance of global polycentric data, and warns latecomers who try to enter the US market with low prices; On the other hand, the incident has also set off a wave
of discussions on whether domestic pharmaceutical companies should prepare for overseas and establish full communication with overseas regulators.

Regardless of whether it is successful or not, it has become a significant stroke in the history of Chinese medicine's overseas expansion, and has an important wind vane role and milestone significance

However, this "failure" does not need to be overly pessimistic, the value of the industry is much greater than the individual tragedy and joy, and the failure story is far more warning and promoting the development of
the industry than the success story.

02The legendary CAR-T successfully went to sea, and innovative drugs went overseas to rekindle confidence

After the "first domestic PD-1 broke through the FDA" halfway, the industry bluntly said that nothing can alleviate the anxiety
of Chinese innovative pharmaceutical companies more than a successful overseas launch.

Fortunately, soon came the good news
that the first domestic CAR-T successfully went to sea.
On February 28, Legend Bio's CAR-T product Cilta-cel received FDA approval for the treatment of relapsed or refractory multiple myeloma (R/R).
MM) patient, became the first cell therapy product
independently developed in China and launched in the United States.

At a time when domestic new drugs such as PD-1 encountered setbacks when they went overseas, confusion and doubts plagued China's innovative drugs, and the approval of Legendary Biotech was a shot in the arm in an almost exemplary way: China's innovation can go out of world-class biotech
.

China's innovation can go beyond world-class biotech

This has also become another "new milestone" in November 2019 after zebratinib set a "zero breakthrough" in China's new drugs going overseas
.
The news of the legendary success at sea has also boosted the sluggish morale of the domestic biomedical circle to a certain extent, making the Chinese pharmaceutical industry boil.

03 A number of domestic pharmaceutical companies were included in the tentative list of the Foreign Companies Accountability Law

In March, the U.
S.
Securities and Exchange Commission (SEC) added five Chinese companies to the tentative list of the Foreign Companies Accountability Act, including well-known pharmaceutical companies
such as BeiGene, Zai Lab, and Hutchison.
The list has been expanded to cover a wider
range of biomedical companies.

Not only that, compared with the threat of the "list" of the US stock market, domestic biopharmaceutical companies are also shrouded in more "name" shadows
.
In February this year, CXO company WuXi Biologics was placed on the U.
S.
"Unverified List" (VUL).

For biopharmaceutical enterprises, the importance of "globalization" is almost self-evident and has gradually become an industry feature
.
However, since the beginning of this year, the US government has introduced a series of challenging policies for China's pharmaceutical industry, which has made everyone more and more aware that technology and science have no borders, but technology and science are done in different countries, and at the same time, Chinese innovative pharmaceutical companies have a deeper and clearer
understanding of overseas financing channels.

Whether it is the capital market or the upstream and downstream of the industry, the trend of institutional constraints is becoming more and more obvious
.
Between the "freedom" and "unfreedom" of globalization, domestic pharmaceutical companies cannot be
separated.

04 Hengrui Zou Jianjun's departure leads to butterfly effect?

Since April this year, after the resignation of Zou Jianjun, then deputy general manager of Hengrui, due to personal reasons, Hengrui has started a series of executive changes in 2022, especially the R&D line
.
Among them, Zou Jianjun, Tao Weikang, Zhang Xiaojing and other executives left
one after another.

A series of executive changes make Hengrui need to reorganize the logic of talent
.
As a result, Hengrui launched the 2022 employee stock ownership plan to encourage core talents
.

At the same time, behind the departure of a series of senior executives of Hengrui, a topic that has attracted much attention has also been opened: in today's innovation-oriented environment, how should traditional pharmaceutical companies build their own talent system?

In today's innovation-oriented environment, how should traditional pharmaceutical companies build their own talent system?

In this regard, Sun Piaoyang, then chairman of Hengrui, mentioned at the 2022 enlightenment meeting that talent competition is mainly solved by incentive mechanisms, but the innovation of an enterprise cannot completely rely on one person or several people to solve the problem, and a complete innovation system must be in order to produce continuous and stable innovation
.
It is necessary to focus on the management of the entire talent system and build a complete technology platform, because in order to make real innovation, there must be a continuous accumulation of technology platforms
.
Hengrui's series of executive changes may be glimpsed from its remarks
.

05 Strong alliance in the field of traditional Chinese medicine: China Resources acquired Kunyao

A "strong alliance" in the field of traditional Chinese medicine was born, and China Resources opened up another way and acquired Kunyao, leaving the market with unlimited speculation
.

In May, KunYao Group issued an announcement that Holley Pharmaceutical and its concerted actor, Holley Group, had signed a Share Transfer Agreement with China Resources Sanjiu
.
According to the agreement, Holley Pharmaceutical and Holley Group transferred their total 212,311,616 shares (accounting for 28% of the total issued shares of KunYao Group) to CR Sanjiu
.
The total price of the underlying shares was RMB2.
902 billion, corresponding to a transfer price of RMB13.
67
per share.
With this acquisition, the A-share traditional Chinese medicine listed group KunYao has turned around and may become a central enterprise holding enterprise
.

The "China Resources Acquisition of KunYao" not only changes the current pattern of the traditional Chinese medicine industry, but also makes the layout of the traditional Chinese medicine sector with the two large central enterprises of Sinopharm go further, and also allows the industry to see the certainty and potential
in the development of the traditional Chinese medicine industry in the new cycle and new ecology of the development of the pharmaceutical industry.

The "China Resources Acquisition of KunYao" not only changes the current pattern of the traditional Chinese medicine industry, but also makes the layout of the traditional Chinese medicine sector with the two large central enterprises of Sinopharm go further, and also allows the industry to see the certainty and potential in the development of the traditional Chinese medicine industry in the new cycle and new ecology of the development of the pharmaceutical industry

Among them, local state-owned assets and central enterprises with resource advantages are in the forefront
.
The "win-win" situation seems to provide a compass
for the industry.

06 Zhongsheng M&A of F-star: The first cross-border acquisition in 2022

Cross-border mergers and acquisitions have always been an important means
for enterprises to develop and grow and achieve international breakthroughs.

In June, China Biopharma announced that its wholly-owned subsidiary, invoX Pharma, had partnered with overseas F-star Therapeutics entered into a merger agreement and plan to acquire all of F-star's outstanding common shares for a total consideration of approximately US$161 million in cash, or approximately RMB1.
08 billion, making it the first cross-border biopharmaceutical acquisition
since the beginning of 2022.

At present, in an external environment where geopolitics is not yet clear, the acquisition has not yet been completed
.
However, the "acquisition of Nasdaq-listed Biotech by a large Chinese pharma" has given the imagination of the capital market and has certain symbolic significance
.

The acquisition of Nasdaq-listed Biotech by a large Chinese pharma has given the imagination of the capital market and has certain symbolic significance

"Acquiring all outstanding shares of a Starkey-listed Biotech is more cost-effective
than a BD product.
" For this transaction, whether from the perspective of price or the quality of the acquisition target, many investors have given full affirmative support, and it has also triggered discussions in the industry on the path of China's traditional large pharmaceutical companies to go overseas
.
To solve the dilemma of innovative drug research and development through epitaxial mergers and acquisitions, Zhongsheng gave its own answer
.

07 Genting Xinyao sells Trop-2: Time is its "positive" name

Time for "one buy and one sell" Genting Xinyao "positive"
.

On August 15, Genting Xinyao announced that it has entered into a termination and transition services agreement with Immunomedics, a subsidiary of Gilead, to transfer TROP-2, which was previously introduced from Immunomedics Asian rights
of the ADC drug Trodelvy ®.
Under the agreement, Genting Xinyao will receive consideration totalling US$455 million, including an upfront payment of US$280 million (subject to relevant regulatory approvals) and US$175 million for potential future milestones, in addition to which Genting Xinyao will not have to pay any previous payments The remaining high-end milestone payment in the license-in transaction was $710 million
.

At that time, everyone had not yet seen the intention of Genting Xinyao's move, and there were many doubts, and the stock price also fell
.
While almost all innovative pharmaceutical companies were excited about the launch of their first innovative drugs, summoned up the courage to embark on a new journey of commercialization, and made unremitting efforts to realize the dream of biopharma, Genting Xinyao "bucked the trend" and "returned" its product rights
.

Time is the best proof
.
Looking back, Genting Xinyao bought and sold, but created a good story, it predicted the cold winter in advance, stockpiled food, and was a successful cold winter under the broken arm to survive
.
From the perspective of history, this is a wise move
.

08 Jimin trusted AR degrader authorized gene tech

Jimin Trust is a traditional pharmaceutical company that constantly refreshes the industry's awareness
.

On August 18, Shanghai Jiyu, a subsidiary of Jimin Trust, entered into a cooperation agreement with Genentech to license the global rights
of its oral androgen receptor (AR) degrader JMKX002992.
Under the agreement, Genentech will make an upfront payment of $60 million to Shanghai Jiyu, up to a milestone of $590 million
.

Surprisingly, although this pharmaceutical company has been ranked in the top 100 of China's top 100 pharmaceutical industries for many years, there is not much
awareness of its innovation ability.
This move is quite a blockbuster, a traditional pharmaceutical company that is almost incompatible with innovation has opened its own "fast" innovation road, and has been recognized
by the world's big pharmaceutical companies.
Through this external licensing transaction, the market's perception of its traditional enterprises has been changed, and Jimin's credible innovation and innovation strength has stood out
among many domestic biotech companies.

It is worth mentioning that in the process of innovation and transformation, Jimin Credible, who "crosses the river by feeling the stones", provides a new idea for the transformation of many traditional pharmaceutical companies, that is, it is necessary to combine the existing Big of the enterprise Pharma's commercialization expertise should be integrated with Biotech's R&D advantages
.

In the process of innovation and transformation, Jimin Credible, who "crosses the river by feeling the stones", provides a new idea for the transformation of many traditional pharmaceutical companies, that is, it is necessary to combine the existing Big of the enterprise Pharma's commercialization expertise should be integrated with Biotech's R&D advantages

09 Cowang Factory: Pandora's Box Opens

In September, just over a year after its completion, Kewang sold its Suzhou process development and production base to WuXi Biologics, which on the one hand made many investors "embarrassed", and on the other hand, it seemed to open the "Biotech factory" Pandora's box
.

Since the second half of the year, there has been a Kewang selling factory, the Suzhou industrialization base of Ji Stone Pharmaceutical has stopped work, and the Hebo Pharmaceutical Factory has sold pipelines.
.
.
All of them have aroused widespread concern in public opinion
.
The above shutdown or factory sale events will not be an exception, and the shuffle period is far from over
.

As a result, it has also triggered the in-depth industry introspection
of how the biotechs that have started to build factories should choose when the "large-scale, large-area, large-investment production base construction" and "the naked survival dilemma of biotechs under the cold winter of capital" collide.

Behind the wave of Biotech factory closures, it is not only the "self-harm" transformation of enterprises, but also strives to overcome the difficulties
.
In fact, a series of events also makes "not all biotech necessarily big.
" Pharma "became clearer and clearer, and gradually became the consensus
of the industry.
In the process, the positioning of both Biotech and Pharma became
clearer.

A series of events also makes it "not all biotech has to be Big.
" Pharma "became clearer and clearer, and gradually became the consensus of the industry

A peculiar sight at the end of October: "new crown miracle medicine" ibuprofen

A peculiar sight occurred in the late month
of 2022.
With the release of the epidemic, ibuprofen has become a "new crown miracle medicine" in one fell swoop, and it is even difficult to find
a pill in many places.
Today's scene, probably a few years from now, is enough to make people talk about
it.

Stuart Adams, the father of ibuprofen, may not have imagined that a painkiller he screened after a hangover could become a "must-have" for the coronavirus epidemic more than 60 years later
.
The leading stocks of the first echelon of ibuprofen have risen from rising to "crazy", and the limelight is unmatched
.

Behind the phenomenon, there are also many thought-provoking questions: as a global producer and exporter of ibuprofen APIs, why is it that drugs cannot be purchased repeatedly? For example, ibuprofen and other antipyretic drugs can solve the problem, do you still need new crown specific drugs?

As a global producer and exporter of ibuprofen APIs, why is it that drugs cannot be purchased repeatedly? For example, ibuprofen and other antipyretic drugs can solve the problem, do you still need new crown specific drugs?

The questions of the masses still need to be solved, and the country is still experiencing large-scale infections, and I hope that the many problems exposed at the end of 2022 will be solved in 2023
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.